Search Results 651-660 of 18368 for Lactation

1. Untitled

   Page 1.

2. A Randomized Multicenter Study for Isolated Skin Vasculitis - Mayo Clinic

   Pregnant or lactating women. Participating Mayo Clinic locations. Study statuses change often. Please contact the study team for the most up-to-date ...

3. VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM - Mayo Clinic

   Women who are pregnant or lactating. Patients unable to undergo an MRI of the brain with contrast. Participating Mayo Clinic locations. Study statuses change ...

4. Effects of Aprepitant on Satiation, Gastric Volume, Gastric Accommodation and Gastric Emptying - Mayo Clinic

   Female subjects must have negative urine pregnancy tests and must not be lactating prior to receiving study medication and radiation exposure; For females ...

5. A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

   Female subjects who can become pregnant (or are already pregnant or lactating), unless they have a negative serum pregnancy test before enrollment and agree to ...

6. Investigational Trial To Evaluate XC001 Delivered Via An Cardiac Catheter In Subjects With Chronic Angina. - Mayo Clinic

   Pregnancy or currently lactating. 15. Receiving an investigational intervention or participating in another clinical trial within 30 days or within 5 half ...

7. Phase I/II Study Of The Combination Of Blinatumomab And Asciminib In Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia - Mayo Clinic

   Pregnant and lactating women will not be eligible; women of childbearing potential should have a negative pregnancy test prior to entering on the study and ...

8. MRI Study To Identify Functional and Structural Changes That Correlate with Patient Improvement When Imaging the Brain Pre-and-Post Erenumab - Mayo Clinic

   Lactation. Not willing to use a reliable form of contraception (for women of childbearing potential) through 16 weeks after the last dose of erenumab ...

9. A Study to Evaluate the Effectiveness and Safety of RalinEpag for Improving Treatment Outcomes in PAH Patients - Mayo Clinic

   Women who are pregnant, lactating or breast-feeding. Note: Other protocol defined Inclusion/Exclusion criteria may apply. Eligibility last updated 6/1/23 ...

10. A Study to Evaluate The Effectiveness and Safety of Abrocitinib, with or without Topical Medications, in Subjects Aged 12 Years and Older with Moderate-to-Severe Atopic Dermatitis - Mayo Clinic

    ... lactating. The following conditions apply: Female subjects of childbearing potential must have a confirmed negative pregnancy test prior to randomization ...